Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalOperating MarginReturn on AssetsReturn on Capital EmployedReturn on Equity

Seres Therapeutics (MCRB) EBT Margin (2016 - 2025)

Historic EBT Margin for Seres Therapeutics (MCRB) over the last 9 years, with Q3 2025 value amounting to 6227.64%.

  • Seres Therapeutics' EBT Margin changed N/A to 6227.64% in Q3 2025 from the same period last year, while for Sep 2025 it was 28834.76%, marking a year-over-year increase of 1658839900.0%. This contributed to the annual value of 150.61% for FY2023, which is 24149900.0% up from last year.
  • Seres Therapeutics' EBT Margin amounted to 6227.64% in Q3 2025.
  • Over the past 5 years, Seres Therapeutics' EBT Margin peaked at 53.86% during Q3 2021, and registered a low of 54770.31% during Q4 2023.
  • For the 4-year period, Seres Therapeutics' EBT Margin averaged around 7800.15%, with its median value being 1741.26% (2022).
  • Data for Seres Therapeutics' EBT Margin shows a peak YoY increase of 53366000bps (in 2023) and a maximum YoY decrease of -545449800bps (in 2023) over the last 5 years.
  • Over the past 4 years, Seres Therapeutics' EBT Margin (Quarter) stood at 688.06% in 2021, then skyrocketed by 67bps to 225.33% in 2022, then crashed by -24206bps to 54770.31% in 2023, then skyrocketed by 89bps to 6227.64% in 2025.
  • Its EBT Margin stands at 6227.64% for Q3 2025, versus 54770.31% for Q4 2023 and 13552.9% for Q3 2023.